WordNet

a silvery soft waxy metallic element of the alkali metal group; occurs abundantly in natural compounds (especially in salt water); burns with a yellow flame and reacts violently in water; occurs in sea water and in the mineral halite (rock salt) (同)Na, atomic number 11

PrepTutorEJDIC

ソジウム,ナトリウム(金属元素;化学記号はNa)

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/11/06 20:15:06」(JST)

wiki en

Faropenem is an orally active beta-lactam antibiotic belonging to the penem group.^[1] It is resistant to some forms of extended-spectrum beta-lactamase.^[2] It is available for oral use.^[3]

Forms

Faropenem was developed by Daiichi Asubio Pharma, which markets it in two forms.

The sodium salt faropenem sodium, available under the trade name Farom, has been marketed in Japan since 1997. (PubChem 636379)

The prodrug form faropenem medoxomil^[4] (also known as faropenem daloxate) has been licensed from Daiichi Asubio Pharma by Replidyne, which plans to market it in conjunction with Forest Pharmaceuticals. The trade name proposed for the product was Orapem, but company officials recently announced this name was rejected by the FDA.^[5]

Clinical use

Faropenem has yet to receive marketing approval in the United States, and was submitted for consideration by the United States Food and Drug Administration (FDA) on 20 December 2005. The new drug application dossier submitted included these proposed indications:

acute bacterial sinusitis
community-acquired pneumonia
acute exacerbations of chronic bronchitis
uncomplicated skin and skin structure infections
urinary tract infections

History

The FDA refused to approve faropenem, an antibiotic manufactured by Louisville-based Replidyne. The FDA said the drug was “nonapprovable”, but did not refer to specific safety concerns about the product. The company will have to conduct new studies and clinical trials, lasting an estimated two more years, to prove the drug treats community-acquired pneumonia, bacterial sinusitis, chronic bronchitis, and skin infections.

References

^ Critchley IA, Brown SD, Traczewski MM, Tillotson GS, Janjic N (December 2007). "National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study". Antimicrob. Agents Chemother. 51 (12): 4382–9. doi:10.1128/AAC.00971-07. PMC 2168020. PMID 17908940.
^ Mushtaq S, Hope R, Warner M, Livermore DM (May 2007). "Activity of faropenem against cephalosporin-resistant Enterobacteriaceae". J. Antimicrob. Chemother. 59 (5): 1025–30. doi:10.1093/jac/dkm063. PMID 17353220.
^ Milazzo I, Blandino G, Caccamo F, Musumeci R, Nicoletti G, Speciale A (March 2003). "Faropenem, a new oral penem: antibacterial activity against selected anaerobic and fastidious periodontal isolates". J. Antimicrob. Chemother. 51 (3): 721–5. doi:10.1093/jac/dkg120. PMID 12615878.
^ Gettig JP, Crank CW, Philbrick AH (January 2008). "Faropenem medoxomil". Ann Pharmacother 42 (1): 80–90. doi:10.1345/aph.1G232. PMID 18094341.
^ (Q1 06 Investor Conf Call)(PubChem 6918218)

External links

Replidyne website
Daiichi Asubio Pharma products page

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. バーター症候群およびギテルマン症候群 bartter and gitelman syndromes
2. 急性腎障害（急性腎不全）におけるナトリウム（FENa）、尿素（FEUrea）、およびその他分子の排泄率 fractional excretion of sodium urea and other molecules in acute kidney injury acute renal failure
3. 腎集合管ナトリウムチャンネルの遺伝的障害：リドル症候群および偽性低アルドステロン症1型 genetic disorders of the collecting tubule sodium channel liddles syndrome and pseudohypoaldosteronism type 1
4. 低ナトリウム血症を有する成人の評価 evaluation of adults with hyponatremia
5. 成人における体液量減少の病因、臨床症状、および診断 etiology clinical manifestations and diagnosis of volume depletion in adults

English Journal

Synthesis, characterization and antibacterial activities of some new ferrocene-containing penems.

Long B, He C, Yang Y, Xiang J.SourceCollege of Chemistry and Chemical Engineering, and Biomedical Engineering Center, State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, Changsha 410082, China.
European journal of medicinal chemistry.Eur J Med Chem.2010 Mar;45(3):1181-8. Epub 2009 Dec 28.
The synthesis and structure-activity relationships of a series of new penems bearing ferrocenyl group attached to the C-2 position of the penem nucleus were described. The beta-lactanic derivatives obtained had been characterized as sodium salts, through (1)H NMR and IR, as well as through element a
PMID 20053481

Gateways to clinical trials.

Tomillero A, Moral MA.AbstractGateways to clinical trials is a guide to the most recent trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity(R), the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: (+)-Dapoxetine hydrochloride, (S)-Tenatoprazole sodium salt monohydrate 19-28z, Acotiamide hydrochloride hydrate, ADV-TK, AE-37, Aflibercept, Albinterferon alfa-2b, Aliskiren fumarate, Asenapine maleate, Axitinib; Bavituximab, Becatecarin, beta-1,3/1,6-Glucan, Bevacizumab, Bremelanotide; Calcipotriol/betamethasone dipropionate, Casopitant mesylate, Catumaxomab, CDX-110, Cediranib, CMD-193, Cositecan; Darinaparsin, Denosumab, DP-b99, Duloxetine hydrochloride; E75, Ecogramostim, Elacytarabine, EMD-273063, EndoTAG-1, Enzastaurin hydrochloride, Eplerenone, Eribulin mesilate, Esomeprazole magnesium, Etravirine, Everolimus, Ezetimibe; Faropenem daloxate, Febuxostat, Fenretinide; Ghrelin (human); I-131 ch-TNT-1/B, I-131-3F8, Iclaprim, Iguratimod, Iloperidone, Imatinib mesylate, Inalimarev/Falimarev, Indacaterol, Ipilimumab, Iratumumab, Ispinesib mesylate, Ixabepilone; Lapatinib ditosylate, Laquinimod sodium, Larotaxel dehydrate, Linezolid, LOR-2040; Mapatumumab, MKC-1, Motesanib diphosphate, Mycophenolic acid sodium salt; NK-012; Olanzapine pamoate, Oncolytic HSV, Ortataxel; Paclitaxel nanoparticles, Paclitaxel poliglumex, Paliperidone palmitate, Panitumumab, Patupilone, PCV-9, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Pertuzumab, Picoplatin, Pimavanserin tartrate, Pimecrolimus, Plerixafor hydrochloride, PM-02734, Poly I:CLC, PR1, Prasugrel, Pregabalin, Progesterone caproate, Prucalopride, Pumosetrag hydrochloride; RAV-12, RB-006, RB-007, Recombinant human erythropoietin alfa, Rimonabant, Romidepsin; SAR-109659, Satraplatin, Sodium butyrate; Tadalafil, Talampanel, Tanespimycin, Tarenflurbil, Tariquidar, Taurine, Tecovirimat, Telatinib, Telavancin hydrochloride, Telcagepant, Terameprocol, Tesofensine, Tetrodotoxin, Tezampanel, Tipifarnib, TPI-287, Tremelimumab; Valspodar, Vatalanib succinate, VCL-CB01, vCP1452, Vorinostat; XL-228; Ziprasidone hydrochloride.
Methods and findings in experimental and clinical pharmacology.Methods Find Exp Clin Pharmacol.2008 Oct;30(8):643-72.
Gateways to clinical trials is a guide to the most recent trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity(R), the drug discovery and development portal, http://integrity.prous.com. Thi
PMID 19088949

Japanese Journal

小児伝染性膿痂疹に対するファロペネムナトリウム(ファロム^【○!R】ドライシロップ小児用)の臨床的有用性の検討

野崎誠,幸田太,佐々木りか子
日本小児皮膚科学会雑誌 = Journal of pediatric dermatology 27(1), 35-39, 2008-05-31
NAID 10024137666

高齢者におけるfaropenem sodiumの体内動態ならびに安全性の検討

柴孝也,加治木章,原田泰子,原田進,高本正祇,宮崎三弘,小山優,山田陽介,千田守,山本俊信,鈴木幹三,谷川原祐介
日本化学療法学会雜誌 = Japanese journal of chemotherapy 50(10), 640-645, 2002-10-25
NAID 10010298991

「ファロペネム」

Faropenem
Clinical data
AHFS/Drugs.com	International Drug Names
Legal status	?
Routes	Oral
Identifiers
CAS number	106560-14-9
ATC code	J01DI03
PubChem	CID 65894
ChemSpider	59303
UNII	F52Y83BGH3
ChEBI	CHEBI:51257
ChEMBL	CHEMBL556262
Chemical data
Formula	C12H15NO5S
Mol. mass	285.317 g/mol
	SMILES O=C2N1/C(=C(\S[C@@H]1[C@H]2[C@H](O)C)[C@@H]3OCCC3)C(=O)O;
	InChI InChI=1S/C12H15NO5S/c1-5(14)7-10(15)13-8(12(16)17)9(19-11(7)13)6-3-2-4-18-6/h5-7,11,14H,2-4H2,1H3,(H,16,17)/t5-,6-,7+,11-/m1/s1 ; Key:HGGAKXAHAYOLDJ-FHZUQPTBSA-N ;
(what is this?) (verify)

　　[★]

英: faropenem sodium, FRPM
化: ファロペネムナトリウム, faropenem sodium
商: ファロム

「FRPM」

　　[★] ファロペネム, faropenem sodium

[pmid17908940-1] Critchley IA, Brown SD, Traczewski MM, Tillotson GS, Janjic N (December 2007). "National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study". Antimicrob. Agents Chemother. 51 (12): 4382–9. doi:10.1128/AAC.00971-07. PMC 2168020. PMID 17908940.

[pmid17353220-2] Mushtaq S, Hope R, Warner M, Livermore DM (May 2007). "Activity of faropenem against cephalosporin-resistant Enterobacteriaceae". J. Antimicrob. Chemother. 59 (5): 1025–30. doi:10.1093/jac/dkm063. PMID 17353220.

[pmid12615878-3] Milazzo I, Blandino G, Caccamo F, Musumeci R, Nicoletti G, Speciale A (March 2003). "Faropenem, a new oral penem: antibacterial activity against selected anaerobic and fastidious periodontal isolates". J. Antimicrob. Chemother. 51 (3): 721–5. doi:10.1093/jac/dkg120. PMID 12615878.

[pmid18094341-4] Gettig JP, Crank CW, Philbrick AH (January 2008). "Faropenem medoxomil". Ann Pharmacother 42 (1): 80–90. doi:10.1345/aph.1G232. PMID 18094341.

[5] (Q1 06 Investor Conf Call)(PubChem 6918218)

匿名

検索

案内

案内

faropenem sodium